NIEMANN-PICK DISEASE DRUG TYPE C TREATMENT MARKET ANALYSIS

Niemann-Pick Disease Drug Type C Treatment Market, by Drug Type (Phase III Drug {Trappsol Cyclo, IB1001}, Marketed Drug {Miglustat (Zavesca)}), by Indication (Niemann-Pick Disease Drug Type C1, Niemann-Pick Disease Drug Type C2), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI4275
Pages :362
Formats :
Excel and PDF
Industry : Pharmaceutical

Niemann-Pick Disease Drug Type C Treatment MarketSize and Trends

Global Niemann-Pick Disease Drug Type C Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 625 million cases and 6.56 million deaths due to coronavirus (COVID-19) were reported till October 25, 2022, across the globe.

Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at US$ 45.40 million in 2022, and is expected to exhibit a CAGR 22.0 % over the forecast period (2022-2030).